Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Asks FDA To Mull Expansion Of NRT Indications

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's Consumer Health division calls on FDA to consider expanding indications and use of over-the-counter nicotine replacement therapies to maximize the public health benefit
Advertisement

Related Content

FDA Asks For Road Map To Broader NRT Indications
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
CDER-Tobacco Center Joint Meeting Could Signal Talks On NRT Indications
NRT Petition Calls On FDA To Greatly Expand Indications, Availability
U.K. NRT Harm Reduction Indication Could Be Model For U.S.
GSK supports smoking cessation campaign
Glaxo Nicorette Ads Say NRTs Can Make Quitting "Suck Less"
Nicotine Patch Plus Lozenge Tops GSK Cessation Options - Study
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation

Topics

Advertisement
UsernamePublicRestriction

Register

PS103593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel